Portrait of Natalie Wu
  • Telehealth visits
bch logo

Natalie Wu, MD, MS

Pediatric Hematology-Oncology
Pediatric Oncology Oakland
877-822-4453
Portrait of Natalie Wu
Portrait of Natalie Wu
bch logo

Natalie Wu, MD, MS

Pediatric Hematology-Oncology
Pediatric Oncology Oakland
877-822-4453

On this page

About me

Dr. Natalie Wu is a pediatric hematologist-oncologist who cares for patients with a variety of childhood cancers. She also provides care in UCSF's survivorship program for patients who have completed their cancer treatment.

Wu's research focuses on the long-term health outcomes of childhood cancer survivors and transplant recipients, seeking to identify patients most at risk for complications later in life.

Wu earned her medical degree at the Oregon Health & Science University School of Medicine. She completed a residency in pediatrics at the McGaw Medical Center of Northwestern University and a fellowship in pediatric hematology-oncology at the University of Washington. She also earned a master's degree in epidemiology from the University of Washington.

Education & training

Board certification

  • Pediatric Hematology-Oncology, American Board of Pediatrics

Fellowship

  • Pediatric Hematology-Oncology, University of Washington School of Medicine

Residency

  • Pediatrics, McGaw Medical Center of Northwestern University

Internship

  • Pediatrics, McGaw Medical Center of Northwestern University

Degree

  • MD, Oregon Health & Science University

Academic Title

  • Health Sciences Clinical Professor

My expertise

  • Specialties
    • Pediatric Hematology-Oncology

Locations

    My research

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

    The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.